[VIRTUAL] LONG TERM OUTCOMES FOR PATIENTS WITH ANAPLASTIC BILATERAL WILMS TUMORS ON AREN0534

[VIRTUAL] LATE TOXICITY COMPARISON OF ALKYLATING-BASED MAINTENANCE WITH CYCLOPHOSPHAMIDE (VAC) VERSUS IFOSFAMIDE (VAI) IN EWING SARCOMA SURVIVORS TREATED IN THE RANDOMIZED CLINICAL TRIAL EURO-EWING99-R1 IN FRANCE

[VIRTUAL] ACADEMIC, PHASE I/II TRIAL ON T CELLS EXPRESSING A THIRD-GENERATION GD2 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE-9 SAFETY SWITCH FOR TREATMENT OF RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA

[VIRTUAL] A PHASE 1/2, OPEN-LABEL STUDY OF REPOTRECTINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ADVANCED OR METASTATIC MALIGNANCIES HARBORING ALK, ROS1, OR NTRK1-3 ALTERATIONS

[VIRTUAL] CIRCULATING TUMOR DNA AS A BIOMARKER IN FAVORABLE HISTOLOGY (FH) WILMS TUMOR (WT) PATIENTS: ANALYSIS FROM CHILDREN'S ONCOLOGY GROUP (COG) TRIAL AREN0533

[VIRTUAL] NAXITAMAB TREATMENT OF REFRACTORY/RELAPSED HIGH-RISK NEUROBLASTOMA (R/R HR NB); SUBGROUP ANALYSIS OF UPDATED INTERIM EFFICACY AND SAFETY DATA FOR THE REGISTRATIONAL PHASE II TRIAL

[VIRTUAL] PREDICTORS OF SEVERE TOXICITY AND POOR EFFICACY OF REINDUCTION CHEMOTHERAPY IN FIRST RELAPSE OF B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AALL1331

[VIRTUAL] OUTCOME AND PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN INFANTS WITH KMT2A-GERMLINE ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ON THE INTERFANT-06 PROTOCOL.

[VIRTUAL] CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY PERSISTS DESPITE REDUCTION OF VINCRISTINE FREQUENCY IN CHILDREN WITH B-ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM CHILDREN'S ONCOLOGY GROUP AALL0932

[VIRTUAL] A THREE-GENE SIGNATURE TO PREDICT SURVIVAL IN PEDIATRIC OSTEOSARCOMAS (OS) AND TO FOLLOW PATIENTS TOWARDS LIQUID BIOPSY: A COLLABORATIVE WORK IN OS2006 SFCE PROTOCOL.

[VIRTUAL] RESULTS FROM AN OPEN-LABEL, PHASE 1/2 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE IN PEDIATRIC PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA

[VIRTUAL] ORAL VINORELBINE EXPOSURE VARIABILITY AMONG PEDIATRIC PATIENTS: POTENTIAL ROLE OF ABCB1, ABCG2, AND UGT2B7 GENETIC VARIANTS.

[VIRTUAL] PHASE II TRIAL OF ORAL VINORELBINE IN CHILDREN WITH PROGRESSIVE OR RECURRENT UNRESECTABLE LOW-GRADE GLIOMA

[VIRTUAL] WHAT DOES A NON-RESPONSE TO INDUCTION CHEMOTHERAPY IMPLY IN HIGH-RISK MEDULLOBLASTOMAS?

[VIRTUAL] LONG-TERM OUTCOMES FOR CHILDREN WITH ATRT TREATED WITH INTENSIVE MULTIMODAL THERAPY: AN UPDATE ON DFCI #02-294